Trials / Completed
CompletedNCT00307567
Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488
A Phase II, Multicentre Booster Study to Evaluate Booster Vaccination With GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or to Evaluate the Immune Memory Following the Administration of a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children, Previously Vaccinated in Infancy in the Primary Study 11PN-PD-DIT-002 (103488)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 689 (planned)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 11 Months – 18 Months
- Healthy volunteers
- Accepted
Summary
Booster and immune memory study
Detailed description
Total: All 689 subjects enrolled in study 103488. 23PS group: Aventis Pasteurs' 23-valent polysaccharide pneumococcal vaccine (Pneumovax 23) + DTPa-HBV-IPV/Hib; 10V group: GSK Biologicals' 10-valent pneumococcal conjugate vaccine + DTPa-HBV-IPV/Hib
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Pneumococcal (vaccine) |
Timeline
- Start date
- 2005-11-01
- Completion
- 2006-03-01
- First posted
- 2006-03-28
- Last updated
- 2016-09-23
Locations
51 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00307567. Inclusion in this directory is not an endorsement.